These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
144 related items for PubMed ID: 3264307
21. HIV env glycoprotein shares a cross-reacting epitope with a surface protein present on activated human monocytes and involved in antigen presentation. Beretta A, Grassi F, Pelagi M, Clivio A, Parravicini C, Giovinazzo G, Andronico F, Lopalco L, Verani P, Buttò S. Eur J Immunol; 1987 Dec; 17(12):1793-8. PubMed ID: 2446880 [Abstract] [Full Text] [Related]
22. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. Klasse PJ, McKeating JA, Schutten M, Reitz MS, Robert-Guroff M. Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803 [Abstract] [Full Text] [Related]
23. Induction of IFN-alpha by HIV-1 in monocyte-enriched PBMC requires gp120-CD4 interaction but not virus replication. Francis ML, Meltzer MS. J Immunol; 1993 Aug 15; 151(4):2208-16. PubMed ID: 8345204 [Abstract] [Full Text] [Related]
24. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biorn AC, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J, Van Ryk DI, Pantophlet R, Burton DR, Freire E, Sodroski J, Chaiken IM. Biochemistry; 2004 Feb 24; 43(7):1928-38. PubMed ID: 14967033 [Abstract] [Full Text] [Related]
25. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Mondor I, Moulard M, Ugolini S, Klasse PJ, Hoxie J, Amara A, Delaunay T, Wyatt R, Sodroski J, Sattentau QJ. Virology; 1998 Sep 01; 248(2):394-405. PubMed ID: 9721247 [Abstract] [Full Text] [Related]
26. Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains. Février M, Boudet F, Deslandres A, Theze J. AIDS Res Hum Retroviruses; 1995 Apr 01; 11(4):491-500. PubMed ID: 7543271 [Abstract] [Full Text] [Related]
27. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Traunecker A, Lüke W, Karjalainen K. Nature; 1988 Jan 07; 331(6151):84-6. PubMed ID: 2829024 [Abstract] [Full Text] [Related]
28. Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to HIV-1-infected quiescent peripheral blood mononuclear cells reveals latent infection. Briant L, Coudronnière N, Robert-Hebmann V, Benkirane M, Devaux C. J Immunol; 1996 May 15; 156(10):3994-4004. PubMed ID: 8621941 [Abstract] [Full Text] [Related]
29. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. Pincus SH, Cole RL, Hersh EM, Lake D, Masuho Y, Durda PJ, McClure J. J Immunol; 1991 Jun 15; 146(12):4315-24. PubMed ID: 1710247 [Abstract] [Full Text] [Related]
33. A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Sánchez-Palomino S, Massanella M, Carrillo J, García A, García F, González N, Merino A, Alcamí J, Bofill M, Yuste E, Gatell JM, Clotet B, Blanco J. Vaccine; 2011 Jul 18; 29(32):5250-9. PubMed ID: 21609746 [Abstract] [Full Text] [Related]
36. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. Lederman S, Gulick R, Chess L. J Immunol; 1989 Aug 15; 143(4):1149-54. PubMed ID: 2545782 [Abstract] [Full Text] [Related]